Regulatory Approval History of Alvogen's Pregabalin Extended-Release Tablets

The U.S. Food and Drug Administration (FDA) recently granted final approval for Alvogen's supplemental labeling application for its Pregabalin Extended-Release Tablets (ANDA 211687). This approval follows the initial approval on July 6, 2021, and subsequent additional approvals on March 2025 and July 17, 2026, as part of ongoing regulatory updates. This generic medication is a copy of Pfizer's blockbuster drug, Lyrica CR (active ingredient: pregabalin extended-release, targeting the voltage-gated calcium channel α2δ subunit), and is available in 82.5mg, 165mg, and 330mg strengths. The FDA's continued approval of label changes suggests a proactive approach by the pharmaceutical company to update the drug's safety profile and the latest clinical information, thereby maintaining its market competitiveness.

Discontinued Marketing Status and Dynamics of the Generic Market

Currently, Alvogen's Pregabalin Extended-Release (ER) is classified as discontinued in the FDA database. Alvogen previously had the opportunity to secure 180 days of exclusive marketing rights as the first generic for this product; however, it failed to launch the product within the specified timeframe and subsequently lost this exclusivity. Nevertheless, Alvogen's continued pursuit and approval of labeling supplements is noteworthy. This can be interpreted as a strategic move to maintain a legal and regulatory foundation for potential future partnerships within the U.S. to re-establish distribution channels or to resume production based on changes in market demand.

Comparison with the Original Lyrica CR and Scope of Indications

Pregabalin extended-release formulations offer improved convenience compared to conventional immediate-release formulations, which require multiple daily doses. The original Lyrica CR is primarily prescribed for the treatment of diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Generic medications must also demonstrate bioequivalence and prove the same safety and efficacy as the original drug to gain approval. Alvogen's product possesses the clear advantage of improved convenience; however, in a market with numerous competing generic manufacturers, it faces structural limitations in regaining market share without a differentiated distribution strategy.

Market and Outlook for Neuropathic Pain Treatment

The global pregabalin market is estimated at approximately $1.76 billion in 2024 and is projected to grow steadily to approximately $2.3 billion by 2032, driven by an aging population and an increase in diabetic patients. However, following the expiration of Pfizer's Lyrica patent, the market has experienced significant price pressure, with numerous Indian and global generic companies engaging in price competition. Alvogen's recent regulatory approval for the label supplement may not immediately translate into increased sales; however, it contributes to protecting the company's value by maintaining a portfolio of drugs for unmet needs in chronic pain treatment. Investors should monitor whether Alvogen announces a future product re-launch or enters into licensing agreements with other distributors.